Paroxetine administration decreases AD-like pathology and reverses memory impairments in a transgenic model of Alzheimer disease

Experimental Neurology

Volumn 207, Issue 1, 2007, Pages 1-3

  Bales, K R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAROXETINE;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; HEALTH CARE; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL;

EID: 34548228426     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.06.005     Document Type: Note

References (21)

1. Alzheimer's Association. Alzheimer's disease Facts and Figures (2007). www.alz.org
2. Berg L., and Morris J.C. Diagnosis. In: Terry R.D., Katzman R., and Bick K.L. (Eds). Alzheimer Disease (1994), Raven Press, New York 9-25
3. 4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival. Exp. Neurol. 203 (2007) 274-278
4. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., and Holtzman D. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48 (2005) 913-922
5. Davies P., and Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
6. Hsieh H., Boeham J., Sato C., Iwatsubo T., Tomita T., Sisodia S., and Malinow R. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
7. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
8. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D., Golde T., and McGowan E. Aβ40 inhibits amyloid deposition in vivo. J. Neurosci. 27 (2007) 627-633
9. Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., and Van Broeckhoven C. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ 42 and decreased Aβ 40. Human Mutat. 27 (2007) 686-695
10. Lanz T.A., Carter D.B., and Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the apoE2 genotype. Neurobiol. Dis. 13 (2003) 246-243
11. Lazarov O., Lee M., Peterson D.A., and SIsodia S.S. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J. Neurosci. 22 (2002) 9785-9793
12. Meziane H., Dodart J.-C., Mathis C., Little S., Clemens J., Paul S.M., and Ungerer. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. 95 (1998) 12683-12688
13. Morris J.C., Storandt M., McKeel D., Rubin E.H., Price J.L., Grant E.A., and Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymtomatic and very mild Alzheimer's disease. Neurology 46 (1996) 707-719
14. Nelson, R.L., Guo, Z., Halagappa, V.M., Pearson, M., Gray, A.J. et al., this issue. Prophylactic treatment with paroxetine ameliotates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol. (doi:10.1016/j.expneurol.2007.01.037).
15. 2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. 271 (1996) 4188-4194
16. Pakaski M., Bjelik A., Hugyecs M., Kasa P., Janka Z., and Kalman J. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem. Int. 47 (2005) 190-195
17. Palmer A. Pharmacotherapy for Alzheimer's disease: progress and prospects. TIPS 23 (2002) 426-433
18. Robert S.J., Zugaza J.L., Fischmeister R., Gardier A.M., and Lezoualc'j F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 266 (2001) 44881-44888
19. Selkoe D.J. Alzheimer's disease: genes, proteins and therapy. Physiol. Rev. 81 (2001) 741-766
20. Sheng J.G., Price D.L., and Kolisatsos V.E. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Aβ amyloidosis. J. Neurosci. 22 (2002) 9794-9799
21. Snyder E.M., Nong Y., Almeida C., Paul S., Moran T., Choi E.Y., Nairn A., Salter M.W., Lombroso P.J., Gouras G.K., and Greengard P. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 81 (2005) 1051-1058